Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - Proteomic and Metabolomic Characterization of COVID-19 Patient Sera MRMHR

ABSTRACT: Targeted mass spectrometric assays for the 22 proteins in a second test cohort containing 19 COVID-19 patients

Dataset imported into MassIVE from https://www.iprox.org/page/project.html?id=IPX0002171000 on 05/30/20

INSTRUMENT(S): TripleTOF 6600

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Tiannan Guo

PROVIDER: MSV000085515 | GNPS | Sat May 30 12:33:00 BST 2020

SECONDARY ACCESSION(S): PXD019232

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.

Shen Bo B Yi Xiao X Sun Yaoting Y Bi Xiaojie X Du Juping J Zhang Chao C Quan Sheng S Zhang Fangfei F Sun Rui R Qian Liujia L Ge Weigang W Liu Wei W Liang Shuang S Chen Hao H Zhang Ying Y Li Jun J Xu Jiaqin J He Zebao Z Chen Baofu B Wang Jing J Yan Haixi H Zheng Yufen Y Wang Donglian D Zhu Jiansheng J Kong Ziqing Z Kang Zhouyang Z Liang Xiao X Ding Xuan X Ruan Guan G Xiang Nan N Cai Xue X Gao Huanhuan H Li Lu L Li Sainan S Xiao Qi Q Lu Tian T Zhu Yi Y Liu Huafen H Chen Haixiao H Guo Tiannan T

Cell 20200528 1

Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using 10 independent patients, 7 of which were correctly classified. Targeted proteomics and metabolomics assays were employe ...[more]

PMID: 32492406

Similar Datasets

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera MRMHR

Project description:Targeted mass spectrometric assays for the 22 proteins in a second test cohort containing 19 COVID-19 patients<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002171000">https://www.iprox.org/page/project.html?id=IPX0002171000</a> on 05/30/20</li></ul>

2020-05-30 | MSV000085515 | MassIVE

Urine proteomics profiling of the COVID-19

Project description:Urine proteomics profiling from the mild and severe COVID-19 patients<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002166000">https://www.iprox.org/page/project.html?id=IPX0002166000</a> on 05/30/20</li></ul>

2020-05-30 | MSV000085516 | MassIVE

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Project description:Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using ten independent patients, seven of which were correctly classified. Targeted proteomics and metabolomics assays were employed to further validate this molecular classifier in a second test cohort of 19 new COVID-19 patients, leading to 16 correct assignments. We identified molecular changes in the sera of COVID-19 patients compared to other groups implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study revealed characteristic protein and metabolite changes in the sera of severe COVID-19 patients, which might be used in selection of potential blood biomarkers for severity evaluation.<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002106000">https://www.iprox.org/page/project.html?id=IPX0002106000</a> on 05/29/20</li></ul>

2020-05-29 | MSV000085507 | MassIVE

GNPS - Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

2020-05-29 | MSV000085507 | GNPS

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

COVID-19 Outbreak

Project description:COVID-19 Outbreak

| PRJNA615625 | ENA

covid-19 study

Project description:covid-19 study

| PRJEB43387 | ENA

Unresolved Immune Dysfunction is Lethal in Both COVID-19 and non-COVID-19 Sepsis

Project description:In this prospective observational cohort study, we found transcriptional evidence that persistent immune dysfunction was associated with 28-day mortality in both COVID-19 and non-COVID-19 septic patients. COVID-19 patients had an early antiviral response but became indistinguishable on a gene expression level from non-COVID-19 sepsis patients a week later. Early treatment of COVID-19 and non-COVID-19 sepsis ICU patients should focus on pathogen control, but both patient groups also require novel immunomodulatory treatments, particularly later during ICU hospitalization, independent of admission diagnosis. Some T1 samples were uploaded in GSE185263 and were not re-uploaded in this series.

2023-03-24 | GSE222393 | GEO

RNA-seq of RBC depleted whole blood from COVID-19 patients and controls

Project description:Red blood cells (RBC) depleted whole blood from COVID-19 patients and controls was harvested and processed in order to performed 10X single cell RNA-seq. For COVID-19 patients 2 samples 10 days a part were analyzed.

2020-08-21 | E-MTAB-9221 | biostudies-arrayexpress

SnoRNAs and miRNAs expression profiles underlying COVID-19 disease severity

Project description:The causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical manifestations in disease-ridden patients. Differences in the severity of COVID-19 ranges from asymptomatic infections and mild cases to the severe form, leading to acute respiratory distress syndrome (ARDS) and multiorgan failure with poor survival. MiRNAs can regulate various cellular processes, including proliferation, apoptosis, and differentiation, by binding to the 3′UTR of target mRNAs inducing their degradation, thus serving a fundamental role in post-transcriptional repression. Alterations of miRNA levels in the blood have been described in multiple inflammatory and infectious diseases, including SARS-related coronaviruses. We used microarrays to delineate the miRNAs and snoRNAs signature in the peripheral blood of severe COVID-19 cases (n=9), as compared to mild (n=10) and asymptomatic (n=10) patients, and identified differentially expressed transcripts in severe versus asymptomatic, and others in severe versus mild COVID-19 cases. A cohort of 29 male age-matched patients were selected. All patients were previously diagnosed with COVID-19 using TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Waltham, Massachusetts), or Cobas SARS-CoV-2 Test (Roche Diagnostics, Rotkreuz, Switzerland), with a CT value < 30. Additional criterion for selection was age between 35 and 75 years. Participants were grouped into severe, mild and asymptomatic. Classifying severe cases was based on requirement of high-flow oxygen support and ICU admission (n=9). Whereas mild patients were identified based on symptoms and positive radiographic findings with pulmonary involvement (n=10). Patients with no clinical presentation were labelled as asymptomatic cases (n=10).

2022-03-01 | E-MTAB-10970 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data